Literature DB >> 33549576

Noonan syndrome patient-specific induced cardiomyocyte model carrying SOS1 gene variant c.1654A>G.

Narasimman Gurusamy1, Sheeja Rajasingh1, Vinoth Sigamani1, Reshma Rajasingh2, Dona Greta Isai3, Andras Czirok3, Douglas Bittel4, Johnson Rajasingh5.   

Abstract

Noonan syndrome (NS) is a dominant autosomal genetic disorder, associated with mutations in several genes that exhibit multisystem abnormal development including cardiac defects. NS associated with the Son of Sevenless homolog 1 (SOS1) gene mutation attributes to the development of cardiomyopathy and congenital heart defects. Since the treatment option for NS is very limited, an in vitro disease model with SOS1 gene mutation would be beneficial for exploring therapeutic possibilities for NS. We reprogrammed cardiac fibroblasts obtained from a NS patient and normal control skin fibroblasts (C-SF) into induced pluripotent stem cells (iPSCs). We identified NS-iPSCs carry a heterozygous single nucleotide variation in the SOS1 gene at the c.1654A > G. Furthermore, the control and NS-iPSCs were differentiated into induced cardiomyocytes (iCMCs), and the electron microscopic analysis showed that the sarcomeres of the NS-iCMCs were highly disorganized. FACS analysis showed that 47.5% of the NS-iCMCs co-expressed GATA4 and cardiac troponin T proteins, and the mRNA expression levels of many cardiac related genes, studied by qRT-PCR array, were significantly reduced when compared to the control C-iCMCs. We report for the first time that NS-iPSCs carry a single nucleotide variation in the SOS1 gene at the c.1654A>G were showing significantly reduced cardiac genes and proteins expression as well as structurally and functionally compromised when compared to C-iCMCs. These iPSCs and iCMCs can be used as a modeling platform to unravel the pathologic mechanisms and also the development of novel drug for the cardiomyopathy in patients with NS.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiomyopathy; Induced cardiomyocytes; Induced pluripotent stem cells; Noonan syndrome; SOS1 gene

Mesh:

Substances:

Year:  2021        PMID: 33549576      PMCID: PMC8542457          DOI: 10.1016/j.yexcr.2021.112508

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  31 in total

1.  A clinical study of Noonan syndrome.

Authors:  M Sharland; M Burch; W M McKenna; M A Paton
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

2.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

3.  Sudden death in a patient with Noonan syndrome.

Authors:  Alper Aydin; Mustafa S Yilmazer; Tayfun Gurol
Journal:  Cardiol Young       Date:  2010-12-22       Impact factor: 1.093

4.  A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.

Authors:  Timon Seeger; Rajani Shrestha; Chi Keung Lam; Caressa Chen; Wesley L McKeithan; Edward Lau; Alexa Wnorowski; George McMullen; Matthew Greenhaw; Jaecheol Lee; Angelos Oikonomopoulos; Soah Lee; Huaxiao Yang; Mark Mercola; Matthew Wheeler; Euan A Ashley; Fan Yang; Ioannis Karakikes; Joseph C Wu
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

5.  Germline gain-of-function mutations in SOS1 cause Noonan syndrome.

Authors:  Amy E Roberts; Toshiyuki Araki; Kenneth D Swanson; Kate T Montgomery; Taryn A Schiripo; Victoria A Joshi; Li Li; Yosuf Yassin; Alex M Tamburino; Benjamin G Neel; Raju S Kucherlapati
Journal:  Nat Genet       Date:  2006-12-03       Impact factor: 38.330

6.  The Noonan syndrome.

Authors:  A Sanchez-Cascos
Journal:  Eur Heart J       Date:  1983-04       Impact factor: 29.983

7.  Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.

Authors:  Fabrice Jaffré; Clint L Miller; Anne Schänzer; Todd Evans; Amy E Roberts; Andreas Hahn; Maria I Kontaridis
Journal:  Circulation       Date:  2019-06-05       Impact factor: 29.690

Review 8.  Cardiovascular disease in Noonan syndrome.

Authors:  Mary Ella Pierpont; Maria Cristina Digilio
Journal:  Curr Opin Pediatr       Date:  2018-10       Impact factor: 2.856

9.  Induction of Human Induced Pluripotent Stem Cells to Cardiomyocytes Using Embryoid Bodies.

Authors:  Takeshi Hatani; Kenji Miki; Yoshinori Yoshida
Journal:  Methods Mol Biol       Date:  2018

Review 10.  Noonan syndrome-causing genes: Molecular update and an assessment of the mutation rate.

Authors:  Ihssane El Bouchikhi; Khadija Belhassan; Fatima Zohra Moufid; Mohammed Iraqui Houssaini; Laila Bouguenouch; Imane Samri; Samir Atmani; Karim Ouldim
Journal:  Int J Pediatr Adolesc Med       Date:  2016-08-18
View more
  4 in total

Review 1.  Translational potential of hiPSCs in predictive modeling of heart development and disease.

Authors:  Corrin Mansfield; Ming-Tao Zhao; Madhumita Basu
Journal:  Birth Defects Res       Date:  2022-03-09       Impact factor: 2.661

2.  Comparative analysis of human induced pluripotent stem cell-derived mesenchymal stem cells and umbilical cord mesenchymal stem cells.

Authors:  Sheeja Rajasingh; Vinoth Sigamani; Vijay Selvam; Narasimman Gurusamy; Shivaani Kirankumar; Jayavardini Vasanthan; Johnson Rajasingh
Journal:  J Cell Mol Med       Date:  2021-08-13       Impact factor: 5.310

3.  In-Silico and In-Vitro Analysis of Human SOS1 Protein Causing Noonan Syndrome - A Novel Approach to Explore the Molecular Pathways.

Authors:  Vinoth Sigamani; Sheeja Rajasingh; Narasimman Gurusamy; Arunima Panda; Johnson Rajasingh
Journal:  Curr Genomics       Date:  2021-12-31       Impact factor: 2.689

4.  Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Authors:  John M Ketcham; Jacob Haling; Shilpi Khare; Vickie Bowcut; David M Briere; Aaron C Burns; Robin J Gunn; Anthony Ivetac; Jon Kuehler; Svitlana Kulyk; Jade Laguer; J David Lawson; Krystal Moya; Natalie Nguyen; Lisa Rahbaek; Barbara Saechao; Christopher R Smith; Niranjan Sudhakar; Nicole C Thomas; Laura Vegar; Darin Vanderpool; Xiaolun Wang; Larry Yan; Peter Olson; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2022-07-14       Impact factor: 8.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.